Core Viewpoint - The China Securities Regulatory Commission (CSRC) has announced an investigation into Yingjixin for misleading statements made during a Q&A session on the Shanghai Stock Exchange's E-interaction platform, emphasizing the need to maintain healthy market development [1]. Group 1: Company Developments - On January 6, 2026, Yingjixin responded to an investor inquiry regarding its involvement in the brain-computer interface (BCI) market, stating that it has entered this field through early investments and has launched the IPA1299 chip, which is designed for high-precision measurement of biological electrical signals [3]. - The IPA1299 chip is an 8-channel, low-noise 24-bit ADC chip that has already been mass-produced and is comparable in performance to leading overseas chip products [3]. - Yingjixin expressed confidence in the broad application prospects of brain-computer interfaces and plans to continue investing resources to achieve breakthroughs in related technologies [3]. Group 2: Market and Regulatory Response - On January 7, Yingjixin provided further clarification, noting that the IPA1299 product is still in the market cultivation phase for non-invasive brain-computer interfaces and has not yet achieved significant sales, which has not materially impacted the company's performance [4]. - Despite acknowledging the uncertainties surrounding this business, Yingjixin's stock rose by 4.51% on January 7 [5]. - The Shanghai Stock Exchange promptly issued a regulatory warning to Yingjixin and its then-secretary of the board, Wu Renchao, following the misleading statements [5]. Group 3: Company Background - Yingjixin was established in 2014 and went public on the Sci-Tech Innovation Board in 2022. Its main business includes power management chips, fast charging protocol chips, data transmission processing chips, wireless signal processing chips, and smart audio-video chips, with applications across various consumer electronics and automotive electronics [5].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into the company, Yingjixin, for misleading statements made during a Q&A session on the Shanghai Stock Exchange's interactive platform [2]. Group 1: Investigation and Compliance - The CSRC announced that it will conduct a comprehensive investigation and take legal action based on the findings to maintain healthy market development [2]. - The company has stated that it will actively cooperate with the CSRC during the investigation and will comply with relevant laws and regulations regarding information disclosure [3]. Group 2: Product Information and Market Status - Yingjixin, in collaboration with its affiliate Jingxin Weier (Changzhou) Electronics Technology Co., Ltd., has launched the IPA1299, an 8-channel low-noise design, 24-bit synchronous sampling analog-to-digital converter (ADC) chip [2]. - The IPA1299 is primarily used for electroencephalogram (EEG), electrocardiogram (ECG), and electromyogram (EMG) applications, featuring high-precision signal acquisition capabilities for non-invasive brain-computer interface (BCI) applications [2]. - The company has issued a risk warning indicating that the product is still in the market cultivation phase and has not yet achieved significant sales, thus not impacting the company's financial performance substantially [2].

Group 1 - The core issue involves Shenzhen Yingjixin Technology Co., Ltd. (referred to as "Yingjixin") being investigated by the China Securities Regulatory Commission (CSRC) for misleading information disclosure related to a self-questioning and answering session on the Shanghai Stock Exchange E-Interaction platform [1] - Yingjixin announced on February 13, 2026, that it received a notice of investigation from the CSRC due to suspected violations of information disclosure laws, and the company will cooperate with the investigation while continuing normal business operations [2] - The company, in collaboration with its affiliate Jingxin Weier (Changzhou) Electronic Technology Co., Ltd., has launched the IPA1299, a low-noise 8-channel 24-bit synchronous sampling analog-to-digital converter (ADC) chip, primarily used in non-invasive brain-computer interface applications [3] Group 2 - The IPA1299 chip is designed for high-precision signal acquisition, applicable in electroencephalography (EEG), electrocardiography (ECG), and electromyography (EMG), with significant technological differences from current invasive brain-computer interfaces [3] - As of the announcement date, the IPA1299 is still in the market cultivation phase for non-invasive brain-computer interfaces and has not yet achieved significant sales, indicating uncertainty in future sales performance [3]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yingjixin Technology Co., Ltd. (Yingjixin) for misleading information disclosure related to its responses on the Shanghai Stock Exchange E-interaction platform [2][4]. Group 1: Investigation Details - On January 6, 2026, Yingjixin was found to have engaged in misleading statements during a Q&A session on the Shanghai Stock Exchange E-interaction platform, leading to the CSRC's decision to investigate [2]. - The CSRC issued a notice of investigation to Yingjixin on February 13, 2026, citing violations of the Securities Law of the People's Republic of China and the Administrative Penalty Law [4]. Group 2: Company Operations - Despite the ongoing investigation, Yingjixin stated that all its business operations are continuing normally and that the company will cooperate with the CSRC during the investigation [4]. - Yingjixin has a product, IPA1299, developed in collaboration with its affiliate, which is an 8-channel low-noise design, 24-bit synchronous sampling analog-to-digital converter (ADC) aimed at applications in EEG, ECG, and EMG [5]. - The IPA1299 product is still in the market cultivation phase for non-invasive brain-computer interface applications and has not yet achieved significant sales, thus not impacting the company's financial performance substantially [5].

Core Viewpoint - The brain-computer interface (BCI) concept is gaining traction, with several listed companies, including Yingjixin, entering the market with new products aimed at this technology [1][2]. Group 1: Company Developments - Yingjixin announced the launch of the IPA1299 chip, a low-noise, 8-channel, 24-bit synchronous sampling analog-to-digital converter (ADC) designed for applications in electroencephalography (EEG), electrocardiography (ECG), and electromyography (EMG) [1]. - The IPA1299 chip is noted for its high-precision signal acquisition capabilities, making it suitable for non-invasive brain-computer interface applications [1]. - The company holds a 15% stake in its partner, Jingxin Weier, which was established in September 2023 with a registered capital of 1.1765 million yuan [1]. Group 2: Market Position and Financials - Yingjixin's revenue for the first three quarters of 2025 was reported at 1.169 billion yuan, with a net profit attributable to shareholders of 114 million yuan [2]. - The company indicated that the IPA1299 chip has already entered mass production and its performance parameters are competitive with leading overseas chip products [2]. - Despite the promising technology, the non-invasive BCI market is still in its cultivation phase, and significant sales have not yet been realized, leading to uncertainty in future sales [1].

Core Viewpoint - The company, 英集芯, has introduced a new product, IPA1299, which is a low-noise, 24-bit synchronous sampling ADC chip designed for non-invasive brain-machine interface applications, although it is still in the market cultivation phase and has not yet achieved significant sales impact on the company's performance [1] Product Overview - The IPA1299 chip supports 8-channel low-noise design and is primarily used for electroencephalogram (EEG), electrocardiogram (ECG), and electromyogram (EMG) applications [1] - The product features high-precision signal acquisition capabilities, making it suitable for various wearable device applications [1] - The technology path of IPA1299 significantly differs from current invasive brain-machine interfaces available internationally [1] Market Status - As of the announcement date, the IPA1299 is still in the market cultivation phase and has not yet achieved large-scale sales [1] - The future sales situation of the product remains uncertain and has not had a major impact on the company's financial performance to date [1]

Core Viewpoint - The company announced the launch of the IPA1299 chip, which supports 8-channel low-noise design and 24-bit synchronous sampling, primarily for applications in EEG, ECG, and EMG, indicating a focus on non-invasive brain-computer interface technology [1] Group 1: Product Details - The IPA1299 chip is developed in collaboration with its affiliate, Jingxin Weier (Changzhou) Electronic Technology Co., Ltd, and is designed for high-precision signal acquisition, suitable for various wearable device applications [1] - The product features a significant technical path difference from current invasive brain-computer interfaces, highlighting its unique position in the market [1] Group 2: Market Status - As of the announcement date, the IPA1299 is still in the market cultivation phase for non-invasive brain-computer interfaces and has not yet achieved large-scale sales [1] - The current sales situation remains uncertain and has not had a significant impact on the company's financial performance [1]

Core Viewpoint - The company, Yingjixin (688209.SH), has announced the launch of the IPA1299 chip in collaboration with its affiliate, Jingxin Weier, which is designed for non-invasive brain-computer interface applications, although it is still in the market cultivation phase and has not yet achieved significant sales impact on the company's performance [1] Group 1: Product Overview - The IPA1299 is an 8-channel low-noise design, 24-bit synchronous sampling analog-to-digital converter (ADC) chip [1] - It is primarily used for electroencephalogram (EEG), electrocardiogram (ECG), and electromyogram (EMG) applications [1] - The product features high-precision signal acquisition capabilities suitable for various wearable device applications [1] Group 2: Market Status - As of the announcement date, the IPA1299 is still in the market cultivation phase for non-invasive brain-computer interfaces [1] - The product has not yet achieved large-scale sales and has not significantly impacted the company's financial performance [1] - Future sales prospects remain uncertain [1]